This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
=== Literary material === In September 2015, Marvel announced the Guidebook to the Marvel Cinematic Universe, named as a nod to the Official Handbook of the Marvel Universe. Each guidebook is compiled by Mike O'Sullivan and the Official Handbook of the Marvel Universe team, with cover art from Mike del Mundo and Pascal Campion, and features facts about the MCU films, film-to-comic comparisons, and production stills. The guidebooks released each month from October 2015 to January 2016 were Guidebook to the Marvel Cinematic Universe: Marvel's Iron Man, Guidebook to the Marvel Cinematic Universe: Marvel's Incredible Hulk / Marvel's Iron Man 2, Guidebook to the Marvel Cinematic Universe: Marvel's Thor, and Guidebook to the Marvel Cinematic Universe: Marvel's Captain America: The First Avenger. In November 2018, Marvel and Titan Publishing Group released Marvel Studios: The First Ten Years to celebrate the first ten years of the MCU. It features cast interviews, in-depth sections on each film, and an Easter egg guide. In October 2021, a two-volume book The Story of Marvel Studios: The Making of the Marvel Cinematic Universe was released, written by Tara Bennett and Paul Terry. This collection features a look at the evolution of Marvel Studios, personal stories from the 23-film "Infinity Saga", and interviews with cast and crew members. In April 2023, W. W. Norton & Company announced MCU: The Reign of Marvel Studios by Joanna Robinson, Dave Gonzales, and Gavin Edwards, for release on October 10, 2023.
Caesium (55Cs) has 41 known isotopes, ranging in mass number from 112 to 152. Only one isotope, 133Cs, is stable. The longest-lived radioisotopes are 135Cs with a half-life of 1.33 million years, 137Cs with a half-life of 30.04 years and 134Cs with a half-life of 2.0650 years. All other isotopes have half-lives less than 2 weeks, most under an hour. Caesium is an abundant fission product (135 and 137 are directly produced) and various isotopes are of concern as such, see the sections below. Beginning in 1945 with the commencement of nuclear testing, caesium radioisotopes were released into the atmosphere, where caesium is absorbed readily into solution and is returned to the surface of the Earth as a component of radioactive fallout. Once caesium enters the ground water, it is deposited on soil surfaces and removed from the landscape primarily by particle transport. As a result, the input function of these isotopes can be estimated as a function of time.
=== Energy intake === 5-HT2C receptor agonists reduce appetite by working on serotonin receptors in a region of the brain called the hypothalamus. Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC, the main pharmacologically active component of cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development due to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects. GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure. Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.
== Bone balance == Acidosis inhibits bone osteoblast matrix mineralization with reciprocal effect on osteoclast activation. The combined responses of these cells to acidosis maximizes the availability of hydroxyl ions in solution that can be used to buffer protons. The utilization of bone to buffer even a small percentage of daily acid production can lead to significant loss of bone mass in the course of a decade. Additionally, as the body ages there is a steady decline in renal function. Metabolic acidosis can become more severe as kidney function weakens, and the body will depend more heavily on bone and blood to maintain acid-base homeostasis.
Sources: en.wikipedia.org
== Bibliography == Szathmary was a prolific writer. From 1978 to 1987, he wrote a Thursday column for the Chicago Sunday Times, as well as a "Chef Louis" column for a wire service that appeared in over one hundred newspapers. He served as an editor for the 1973 edition of the 15-volume "Cookery Americana" series, in addition to writing several of his own cookbooks.
The Aleutians are home to many large colonies of seabirds. Buldir Island has 21 breeding seabird species, including the Bering Sea-endemic red-legged kittiwake. Large seabird colonies are also present at Kiska, Gareloi, Semisopochnoi, Bogoslof, and others. The islands are also frequented by vagrant Asiatic birds, including the common rosefinch, Siberian rubythroat, bluethroat, lanceolated warbler, and the first North American record of the intermediate egret. The habitats of the Aleutians are largely unspoiled, but wildlife is affected by competition from introduced species such as cattle, caribou, and foxes. Nearly all of the Aleutians are protected as part of the Alaska Maritime National Wildlife Refuge and the Aleutian Islands Wilderness. Observations have identified sea otters as a keystone species along the coasts of many of the Aleutian Islands. Their presence encourages the growth of kelp forests, as the otters control sea urchin populations (as large populations of sea urchins can create urchin barrens by clearing away kelp stands).
A founding member of ASEAN and OIC, the country participates in many international organisations such as the United Nations (UN), APEC, the D-8 Organization for Economic Cooperation, and NAM. It has chaired ASEAN, OIC, and NAM in the past. A former British colony, it is also a member of the Commonwealth. Kuala Lumpur was the site of the first EAC in 2005. Malaysia's foreign policy is officially based on the principle of neutrality and maintaining peaceful relations with all countries, regardless of their political system. The government attaches a high priority to the security and stability of Southeast Asia, and seeks to further develop relations with other countries in the region. Historically the government has tried to portray Malaysia as a progressive Islamic nation while strengthening relations with other Islamic states. A strong tenet of Malaysia's policy is national sovereignty and right of a country to control its domestic affairs. Malaysia signed the UN treaty on the Prohibition of Nuclear Weapons. The Spratly Islands are disputed by many states in the area, and a large portion of the South China Sea is claimed by China. Unlike its neighbours of Vietnam and the Philippines, Malaysia historically avoided conflicts with China. However, after the encroachment of Chinese ships in Malaysian territorial waters, and breach of airspace by their military aircraft, Malaysia has become active in condemning China. Brunei and Malaysia in 2009 announced an end to claims of each other's land, and committed to resolve issues related to their maritime borders.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.